A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions



Status:Completed
Conditions:Urology
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:July 2013
End Date:June 2014

Use our guide to learn which trials are right for you!

A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS® 400 mg in Women With Ulcerative Interstitial Cystitis

The purpose of the study is to evaluate if LiRIS 400 mg is safe and tolerable when
administered to women with Interstitial Cystitis with Hunner's lesions, and to evaluate any
change in the bladder or in IC symptoms, following LiRIS administration.


Inclusion Criteria:

- Women age 18 and older

- Interstitial Cystitis with history of Hunner's lesions in the bladder

- Moderate to severe bladder discomfort

- Confirmation of Hunner's lesions in Bladder

- Able to report symptom (pain and voiding frequency) in a diary throughout the study

Exclusion Criteria:

- Pregnant women

- History or presence of bladder cancer

- History or presence of any condition that would make it difficult to evaluate bladder
symptoms
We found this trial at
2
sites
Daytona Beach, Florida 32114
?
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Royal Oak, Michigan 48073
?
mi
from
Royal Oak, MI
Click here to add this to my saved trials